Skip to main content

Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced that Chris Varma, Ph.D., co-founder, chair, and chief executive officer of Frontier Medicines, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:30 p.m. PST.

About Frontier Medicines
Frontier Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically defined patient populations, starting with oncology and immunology. Our proprietary chemoproteomics-powered drug discovery engine, the Frontier™ Platform, leverages covalent chemistry and machine learning to unlock difficult-to-drug, disease-causing proteins for drug development. Today, we are advancing a diversified pipeline of wholly owned precision medicines against the most critical drivers of cancer and high-value immunology programs. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn.

Media Contact
pr@frontiermeds.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  212.79
+3.02 (1.44%)
AAPL  258.86
+2.94 (1.15%)
AMD  220.18
+2.68 (1.23%)
BAC  50.06
+0.68 (1.38%)
GOOG  297.66
+3.20 (1.09%)
META  573.02
-1.44 (-0.25%)
MSFT  372.88
-0.58 (-0.16%)
NVDA  177.64
+0.25 (0.14%)
ORCL  145.54
-0.84 (-0.57%)
TSLA  352.82
-7.77 (-2.15%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.